ORIC Pharmaceuticals. has been granted a patent for CD73 inhibitors, which are pharmaceutical compounds designed for treating cancer, infections, and neurodegenerative diseases. The patent specifically claims a method for treating various types of cancer, including lung, breast, and melanoma, using these compounds. GlobalData’s report on ORIC Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ORIC Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. ORIC Pharmaceuticals's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12018043B2 outlines a method for treating various types of cancer, including lung cancer, melanoma, breast cancer, and multiple myeloma, among others. The treatment involves administering a compound defined by a specific chemical structure, referred to as Formula (I), or a pharmaceutically acceptable salt of that compound. The claims detail various structural components of the compound, including substituents such as halogens, alkynyl groups, and hydroxyalkyl groups, which can be independently modified to enhance therapeutic efficacy. The patent specifies that the compound can be tailored with different substituents at various positions, allowing for a range of chemical variations to potentially improve treatment outcomes.
Further claims elaborate on the specific configurations of the compound, including the nature of substituents R1, R2, R3, R6, and others, which can include alkyl, haloalkyl, and heteroaryl groups. The patent also identifies particular types of leukemia and lymphoma that can be targeted with this treatment, such as acute lymphocytic leukemia and Hodgkin's lymphoma. Additionally, it provides detailed descriptions of multiple myeloma subtypes, including smoldering and non-secretory forms. The comprehensive nature of these claims suggests a focus on the versatility of the compound in addressing a wide spectrum of hematological and solid tumors, potentially offering new avenues for cancer therapy.
To know more about GlobalData’s detailed insights on ORIC Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
